Mirador Capital Partners’s Cytokinetics CYTK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$17.2M Sell
202,370
-303
-0.1% -$21.8K 2.11% 11
2026
Q1
$13.4M Buy
202,673
+4,115
+2% +$262K 1.89% 13
2025
Q4
$12.6M Buy
198,558
+1,191
+0.6% +$74.1K 1.73% 14
2025
Q3
$10.8M Buy
197,367
+53,020
+37% +$2.18M 1.54% 18
2025
Q2
$4.77M Buy
144,347
+45,222
+46% +$1.57M 0.77% 33
2025
Q1
$3.98M Buy
99,125
+33,489
+51% +$1.54M 0.7% 37
2024
Q4
$3.09M Buy
65,636
+1,010
+2% +$52.5K 0.56% 41
2024
Q3
$3.41M Buy
64,626
+1,483
+2% +$82.7K 0.61% 42
2024
Q2
$3.42M Buy
63,143
+27,688
+78% +$1.67M 0.64% 40
2024
Q1
$2.49M Sell
35,455
-13,497
-28% -$1.04M 0.47% 49
2023
Q4
$4.09M Sell
48,952
-6,676
-12% -$242K 0.87% 30
2023
Q3
$1.64M Buy
55,628
+1,890
+4% +$62.9K 0.37% 60
2023
Q2
$1.75M Sell
53,738
-2,846
-5% -$105K 0.42% 61
2023
Q1
$1.99M Sell
56,584
-2,148
-4% -$87.6K 0.47% 52
2022
Q4
$2.69M Sell
58,732
-69,753
-54% -$3M 0.64% 39
2022
Q3
$6.22M Sell
128,485
-35,098
-21% -$1.69M 1.5% 17
2022
Q2
$6.43M Buy
163,583
+4,085
+3% +$164K 1.52% 18
2022
Q1
$5.87M Buy
159,498
+6,879
+5% +$244K 1.19% 21
2021
Q4
$6.96M Sell
152,619
-10,857
-7% -$419K 1.46% 19
2021
Q3
$5.84M Buy
163,476
+4,977
+3% +$147K 1.33% 21
2021
Q2
$3.14M Buy
158,499
+9,415
+6% +$221K 0.71% 46
2021
Q1
$3.47M Sell
149,084
-3,311
-2% -$70.7K 0.89% 37
2020
Q4
$3.17M Buy
152,395
+40,271
+36% +$736K 0.87% 41
2020
Q3
$2.43M Buy
112,124
+16,017
+17% +$375K 0.76% 44
2020
Q2
$2.27M Sell
96,107
-1,247
-1% -$23.4K 0.85% 39
2020
Q1
$1.62M Sell
97,354
-5,122
-5% -$65.3K 0.68% 46
2019
Q4
$1.09M Buy
+102,476
New +$1.05M 0.44% 64

Other funds holding CYTK